Support throughout your BYOOVIZ® treatment

Biogen Biosimilar Support Services can:

  • Provide support in the event of denied insurance claims
  • Educate you on the eligibility details of the Copay Programs,
    which can potentially cover the cost of both your BYOOVIZ
    prescription and treatment procedure
  • Answer other questions you or your family may have about BYOOVIZ

Please note that the Administration Copay Program and Drug Copay Program are different programs with unique eligibility for each. You must enroll separately as needed.

You may be eligible for the Drug Copay Program if you:

  • Have commercial insurance
  • Are a United States resident
  • Are prescribed BYOOVIZ for Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), or Myopic Choroidal Neovascularization (mCNV)
  • Other restrictions apply.*

*There may be an annual cap on the amount of assistance that patients can receive over a one-year period. Your insurance will be billed first and must pay before copay assistance will be applicable. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, VA/DoD, or any other federal plans are not eligible to enroll. Clinical and other restrictions may apply. Patients are eligible to enroll in the Biogen Copay Program for as long as it is offered and they are treated with BYOOVIZ. Please call Biogen Biosimilar Support Services at 1-877-422-8360 for further details.

Please note that the Drug Copay Program and Administration Copay Program are different programs with unique eligibility for each. You must enroll separately as needed.

Individuals on nongovernment insurance may be eligible for the Administration Copay Program. Your healthcare provider must submit a request for treatment using an approved code for administration. Only codes approved by Biogen shall be eligible under the program. Restrictions may apply.†

†Residents of Massachusetts, Minnesota, or Rhode Island are not eligible. Individuals receiving coverage from Medicare, Medicaid, the VA/DoD, TRICARE®, or any other governmental or pharmaceutical assistance are not eligible. TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

For more information about these financial assistance options, contact Biogen Biosimilar Support Services at 1-877-422-8360, Monday through Friday, 8:30 AM–5:00 PM ET.

What is BYOOVIZ® (ranibizumab-nuna) injection?

BYOOVIZ® is a prescription medicine for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein (RVO)
  • Myopic Choroidal Neovascularization

IMPORTANT SAFETY INFORMATION

What Important Safety Information should I know about BYOOVIZ?

You should not use BYOOVIZ if you have an infection in or around the eye or are allergic
to ranibizumab products or any of the ingredients in BYOOVIZ.

BYOOVIZ is a prescription medication given by injection into the eye, and it has side effects.

BYOOVIZ can cause serious side effects, including:

  • Detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your healthcare provider right away
  • Increased eye pressure. Some patients have had increases in eye pressure before and within 1 hour of an injection. Your healthcare provider should check your eye pressure and eye health before and after your BYOOVIZ injection
  • Heart attacks or strokes. There is a potential risk of serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes
  • Severe inflammation of vessels in the retina, with or without blockage, have been reported with the use of ranibizumab products. Call your healthcare provider immediately if you experience any changes in vision
  • Some patients using ranibizumab products have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts

The most common eye-related side effects include:

  • Increased redness in the white of the eye
  • Eye pain
  • Small specks (floaters) in vision
  • Increased eye pressure

The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough.

These are not all of the possible side effects of BYOOVIZ. For more information, ask your doctor. To report side effects to FDA, please call 1-800-FDA-1088. You may also report side effects to Biogen Inc. at 1-877-422-8360.

Please see full Prescribing Information.

Prescribing Information Terms of Use Privacy Policy Contact Us Cookie Policy

©2025 Biogen. All rights reserved. 11/25 BYO-US-0203v2

This site is intended for residents 18 years or older of the United States, Puerto Rico, and US territories.
Lucentis is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.